Dr. Dan T. La, MD
Rheumatology (Rheumatology Physician)
6673 Foothill Blvd
Tujunga, CA 91042
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 830
Licensed in California since 2003, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CA license A84795 (first issued 2003; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Usc Verdugo Hills Hospital Glendale, CA
- Glendale Adventist Medical Center Glendale, CA
- Los Angeles General Medical Center Los Angeles, CA
- Glendale Mem Hospital & Hlth Center Glendale, CA
- Hollywood Presbyterian Medical Center Los Angeles, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 830
- Services billed
- 39,719
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12,450 | 19 |
| Injection, denosumab, 1 mg | 6,120 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,053 | 720 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 447 | 152 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 420 | 60 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 377 | 102 |
| Administration of chemotherapy into vein, each additional hour | 364 | 43 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 312 | 57 |
| Administration of chemotherapy into vein, 1 hour or less | 284 | 43 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 238 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Tujunga, CA | 953 |
| Methotrexate (methotrexate sodium) Other prescribers in Tujunga, CA | 851 |
| Hydroxychloroquine Sulfate Other prescribers in Tujunga, CA | 828 |
| Tramadol Hcl Other prescribers in Tujunga, CA | 757 |
| Prednisone Other prescribers in Tujunga, CA | 536 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Tujunga, CA | 475 |
| Meloxicam Other prescribers in Tujunga, CA | 428 |
| Ibuprofen Other prescribers in Tujunga, CA | 372 |
| Diclofenac Sodium Other prescribers in Tujunga, CA | 330 |
| Allopurinol Other prescribers in Tujunga, CA | 262 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 180 payments worth $5,096 in total to this clinician.
| AbbVie Inc. | $1,291 |
|---|---|
| Amgen Inc. | $657 |
| Novartis Pharmaceuticals Corporation | $485 |
| UCB, Inc. | $418 |
| Pfizer Inc. | $416 |
| GlaxoSmithKline, LLC. | $352 |
| Alexion Pharmaceuticals, Inc. | $350 |
| Janssen Biotech, Inc. | $277 |
| Food and Beverage | $5,096 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $2,365,188 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - A phase 2A, single-arm study to investigate the efficacy and safety of LY3541860 in adult participants with moderately-to-severely active rheumatoid arthritis
Eli Lilly and Company - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
American Regent · Completed · NCT01925261 - A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company · Terminated · NCT05516758 - A phase 4, multicenter, prospective, open-label study describing the e
GlaxoSmithKline, LLC. - A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT06928142 - A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)
Novartis Pharmaceuticals Corporation - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.